Thanks for posting ablm, He's an impressive man is Baker. The...

Thanks for posting ablm,

He's an impressive man is Baker. The clowns running the webinar left out a couple of slides from his deck and he bounced back very well, always considered that trait as being indicative of someone that knows their game.

Interesting to see the latest CAR-T deal (Dec of 23) where Astrazeneka swallowed Gracell for 1.2 billion at Ph1b.

So ALA is (potentially) a global front runner in the cell therapy manufacturing space and has an opportunity for FDA platform designation. I continue to maintain that this achievement has significantly ignored or misunderstood by the market.

Below is a link is the final of a 4-part series on Cell Therapy which identifies risks and (interestingly) the CAR-T pivot from cancers to autoimmune disease

https://www.fiercebiotech.com/biotech/cell-therapy-reckoning-how-get-cell-therapies-flying-shelf





Finally, can't see the results from Ph1 trial being available until Q1,25 although the weekly Heikin Ashi chart looks good.